Possible relation between viruses and oromaxillofacial tumors. III. Demonstration of the SV40 antigen and anti-SV40 antibodies in patients with tumors of the parotid gland

SV40 antigen was detected in 7 of 13 malignant tumors developed in the head and neck region. Specific complement fixing antibodies were found in all the patients with the SV40 antigen present in the parotid gland tumoral cells. Incidence of the anti-SV40 complement fixing antibodies in parotid gland tumor bearing patients was of 69.6%.     

Possible relation between viruses and oromaxillofacial tumors. IV. Presence of the herpes antigen and anti-herpes antibodies in patients with tumors of the parotid gland

The presence of herpesvirus antigen and of antiherpesvirus antibodies was detected in 46% and in 36.3%, respectively, of the patients bearing parotid gland tumors. Very high titers of antiherpesvirus antibodies were found in 70.6% of the patients with nasopharyngeal carcinoma.     

Possible relation between viruses and oromaxillofacial tumors. V. Demonstration of hemagglutination-inhibiting anti-BK virus antibodies in patients with tumors of the parotid gland

Anti-BK-virus hemagglutination inhibiting antibodies were revealed in 81.8% of the patients with parotid gland tumors. Results of the investigations conducted on oromaxillofacial tumors including the parotid gland ones are discussed from the point of view of the presence of viral antigens (herpes-, SV40 and BK-viruses) and of specific antibodies. Possible implication of the papova viruses in the etiopathogenesis of the parotid gland tumors in humans are also discussed.     

Possible relation between viruses and oromaxillofacial tumors. I. Demonstration of herpes antigens and anti-herpes antibodies

Herpes virus type 1 and 2 antigens were detected in cells originating from malignant tumors with oromaxillofacial localization. A higher incidence of type 1 antigens was noted, as compared to the type 2. Investigated antigens were detected more frequently in the tumors of ectodermal origin. Antiherpesvirus FC antibodies were found in 74.5% of the tumor bearing subjects, but only in 22.3% of the controls.     

Investigations on the presence of antibodies to papova viruses in patients with different forms of cancer and in other categories of patients or apparently healthy subjects. Note I. Neutralizing antibodies to SV-40 in the cerebrospinal fluid of patients with brain tumors and chronic neurological diseases

Neutralizing antibodies to SV-40 were detected in cerebrospinal fluid samples from 16 out of 43 patients with brain tumors and in 6 out of 20 patients with different nonmalignant chronic neurological diseases. The patients' age excluded the correlation with a vaccine-associated or occupational contact with SV-40. The results ascertain the occurrence of SV-40 or of an antigenically related virus in the population of Romania.     

Serum antibodies to papova viruses (BK and SV 40) in subjects from the area with Balkan endemic nephropathy

The presence of antibodies to BK virus and SV40 was investigated in 63 patients with Balkan endemic nephropathy (BEN) and in 83 apparently healthy subjects from the endemic area. Serum antibodies to BK virus were detected in 95.2% of the former and in 74.7% of the latter, high antibody levels being prevalent in the age groups 41-60 years. Antibodies to SV40 were absent in the BEN patients and their frequency in the healthy subjects (27.7%) was much lower than that previously recorded in healthy persons from other zones of Romania (40%). The results obtained plead for a prevalence of BK virus infection in the endemic area with BEN.     

Investigations of the presence of serum antibodies to Epstein-Barr virus in patients with various tumors

Serum samples from 150 patients with various malignant or benign tumors and from 20 clinically healthy subjects were tested by indirect immunofluorescence (IF) reaction for the presence of specific antibodies to Epstein-Barr-virus-determined viral capsid antigen (EB VCA). The IF test-carried out in multitest-slide EB3 and Raji cell preparations-revealed antibodies to EB VCA in 102 of the patients with tumors and in 4 of the healthy persons.     

Studies on the presence of viral antibodies in patients with various forms of malignant neoplasia.

The study of viral antibodies in 6714 sera demonstrated that the level of antibodies to infectious viruses was the same in cancer patients as in controls. However, the patients with various forms of neoplasia showed a considerable percentage and high antibody levels to viruses with oncogenic potential for animals (adenovirus, SV40, Rous virus) or involved in human carcinogenesis (herpes virus).     

前列腺增生患者年龄、前列腺体积以及血清PSA的关系分析

目的探讨前列腺增生患者年龄、前列腺体积以及血清前列腺特异性抗原（prostate-specific antigen,PSA）之间的关系。方法回顾2000～2005年204例确诊为前列腺增生的患者临床资料,采用SPSS10．0软件总结并分析患者年龄、前列腺体积以及血清PSA之间关系。结果204例患者平均年龄为（68．78±6．44）岁,平均体积为（57、33±34．12）ml;平均PSA值（6．90±5．81）μg·L^-1;对患者年龄分组后显示前列腺体积、血清PSA值随患者年龄增长而增加（F=3．05,P=0．03;F=2．74,P=0．044）;血清PSA值随前列腺体积增加而升高（F=11．37,P〈0．001）,对患者年龄进行控制后仍然显示PSA值与体积正相关（r=0.31,P〈0.001）。结论前列腺增生患者前列腺体积和血清PSA水平随患者年龄增长而增加,患者血清PSA与前列腺体积正相关。     

青霉素皮肤试验与特异性IgE抗体的相关性

目的：探讨青霉素皮肤试验（皮试）与特异性IgE的相关性，方法：采用放射过敏原吸附试验（RAST）测定青霉素过敏病人血清特异性IgE 抗体，结果：根据皮试与抗体测定时间隔分为4个时间段，即刻，30d内，30d至2年和2年以上，皮试阳性患者各时间段IgE抗体阳性率分别为42．9％，28．6％，18．8％和10．5％，当皮试阳性反应程度≥“＋”时，IgE抗体阳性率为8．3％，皮试与RAST的符合率为66．7％，当反应程度≥“＋＋”时，IgE抗体阳性率为60％，二者符合率为77．8％，皮试程度与血清特异性IgE抗体呈显著相关（P＜0．05），当皮试≥“＋＋＋”时，皮试与RAST完全相符，结论：青霉素皮试的准确性与皮试反应程度及时间有关，RAST可作为青霉素过敏反应体外诊断的一种重要辅助方法。     

The influence of 2,4,6-tribromophenyl isocyanate on the cellular and nuclear uptake of the SV 40 T antigen nuclear localization sequence

The objective of the present study was to evaluate the influence of 2,4,6-tribromophenyl isocyanate (TBPI) on the cellular and nuclear uptake of the fluorescein isothiocyanate (FITC) labeled SV 40 T antigen nuclear localization sequence in human LN18 and U373 glioma cells. Therefore, the FITC-labeled nuclear localization sequence (NLS) of the SV 40 T antigen was coupled to 2,4,6-TBPI. This TBPI-NLS conjugate was taken up by the cell nuclei of more than 90% of human malignant glioma cells. The nuclearly stained cells showed clear signs of cell death. However only up to 10% of the cells were stained after incubation with the TBPI-lacking NLS of the SV 40 T antigen together with free, unbound TBPI. These cells stayed alive. TBPI, when bound to small peptides, may be an important component for future drugs against gliomas.     

男性2型糖尿病患者胰岛素抵抗与前列腺特异性抗原的相关性研究

目的探讨在男性2型糖尿病患者中胰岛素抵抗与前列腺特异性抗原（prostate specific antigen,PSA）的相关性。方法男性2型糖尿病183例,检测空腹血糖（FPG）、空腹胰岛素（FINS）、糖化血红蛋白（HbA1C）、血脂系列（TC、TG、LDL、HDL）、游离前列腺特异性抗原（fPSA）和总前列腺特异性抗原（tPSA）浓度等相关临床指标,计算胰岛素抵抗指数（HOMAIR）、体质指数（BMI）。根据HOMA-IR分为胰岛素抵抗组（IR≥2.8）和非胰岛素抵抗组（IR〈2.8）;根据tPSA的中位数0.732μg/L,将患者分为tPSA≥0.732μg/L组和tPSA〈0.732μg/L组。结果胰岛素抵抗组（69例）患者的BMI明显高于非胰岛素抵抗组（114例）（P〈0.05）,tPSA明显低于非胰岛素抵抗组（P〈0.05）。tPSA≥0.732μg/L组（92例）的BMI、HOMA-IR均低于tPSA〈0.732μg/L组（91例）（均P〈0.05）。tPSA与年龄、fPSA、LDL呈正相关（r分别为0.345、0.865、0.200;均P〈0.05）,与IR、BMI呈负相关（r分别为-0.151、-0.155;均P〈0.05）。结论胰岛素抵抗和肥胖是导致PSA下降的因素。     

Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients

Patients with antibody deficiency disorders are highly susceptible to bacterial infections. Replacement therapy with intravenous immunoglobulin preparations (IVIG) has been established in such patients for two decades. The efficacy of IVIG treatment depends on the amount of functional pathogen-specific antibodies provided. The present study was undertaken to determine the levels of immunoglobulin classes, IgG subclasses, and specific antibodies to bacterial surface antigens in two different IVIG preparations (Sandoglobulin® and Gamimmune®) and blood sera of IVIG-treated immunodeficient patients. The levels of IgG, IgA, IgM and IgG subclasses were determined in both IVIG preparations and in patients’ sera and were compared with those of healthy individuals. Sandoglobulin® contained significantly higher concentrations of IgA, IgG₂ and IgG₄ than Gamimmune®. The latter contained higher concentrations of IgG₁. Patients treated with Gamimmune® had significantly lower concentration of IgG₄ as compared with healthy individuals and Sandoglobulin®-treated patients. This finding was related to the preparation’s composition. Screening of 20 lots from each preparation for antibodies to frequent clinically isolated strains of Escherichia coli, Staphylococcus aureus, S. epidermidis, Klebsiella pneumoniae and Enterococci spp. showed a high lot-to-lot variability. In order to overcome the lot-to-lot variability and correlate the observed effects with each IVIG preparation, the administered IVIG lots were selected so that their titers were in the interval of mean value±S.D. for each pathogen. The two tested preparations showed significant differences in their content of specific antibodies that ultimately affected the levels of these antibodies in treated patients. More specifically, Sandoglobulin® contained higher levels of antibodies to E. coli and S. epidermidis strains. Infusion of this preparation maintained the respective antibodies in the recipients significantly higher than those of healthy individuals. Gamimmune® infusion led to similar and comparable levels. Both IVIG preparations had comparable antibody titers towards K. pneumoniae, provided high amounts of antibodies, and kept recipients’ specific IgG at levels significantly higher than those of the healthy individuals. Enterococci spp. specific antibodies were significantly higher in Gamimmune®, whereas titers of antibodies towards S. aureus were comparable. Levels of antibodies against both Enterococci spp. and S. epidermidis after administration of both preparations were close to those in healthy individuals. None of the patients developed infection during the time of the study. In conclusion, most of the lots of the two IVIG preparations studied, despite some quantitative differences, provide patients with sufficient amounts of antibodies to bacterial surface antigens that protect them against infections.     

青霉素过敏病人血清特异性IgE抗体与青霉素化学结构的关系

本研究采用放射过敏原吸附抑制试验研究青霉素过敏病人血清特异性IgE抗体与青霉素化学结构的关系。通过对 3例高敏病人的研究发现 ,作为青霉素G和青霉素V的侧链结构的苯乙酸 (PHA)和苯氧乙酸 (PHOA)抑制 2例高敏病人血清IgE抗体程度稍弱于青霉素G和青霉素V ,但是高于其他抑制剂。提示病人体内特异性IgE抗体的识别位点与青霉素G和青霉素V侧链关系密切。而另 1例高敏病人抑制试验显示 ,抗体识别位点与整个药物分子结构有关。研究证明 ,特异性IgE抗体在识别青霉素化学结构时 ,有的识别整个药物结构 ,而有的仅识别侧链结构     

Epstein-Barr virus (EBV). X. Incidence of EBV antibodies in patients with malignant tumors

Serum samples from 31 patients with various types of malignancies, 18 patients with different viral infections and 6 healthy subjects as controls, were tested by indirect immunofluorescence (IF) method for antibodies against viral capsid antigens (VCA) and the presence of active EBV infection. EBV antibodies anti-VCA were detected in 19 patients with tumors, in 8 patients with viral infections and in 2 healthy subjects. EBV active infection was found out in 9/19, 3/8 and 0/2 EBV anti-VCA positive patients with malignancies, different viral infections and healthy subjects respectively.     

Epstein-Barr virus (EBV). III. Incidence of EBV antibodies in patients with various tumors

Serum samples from 553 patients with various tumors, from 26 patients with different viral infections and from 78 clinically healthy subjects were tested by indirect immunofluorescence (IF) reaction for the presence of specific antibodies to Epstein-Barr virus. The test revealed antibodies to EBV in 127 patients with tumors, in 14 patients with viral infections and in 8 healthy persons.     

ABO血型与多器官功能衰竭综合征发病易感性的相关性研究

目的探讨ABO血型与多器官功能障碍综合征（multiple organ dysfunction syndrome，MODS）发病易感性的相关性。方法采用回顾性病例对照研究的方法，将61例MODS患者与一般人群31184名ABO血型进行对比分析。结果MODS患者ABO血型分布依次为O型34．43％，B型32．79％，A型29．51％，AB型3．28％；一般人群ABO血型分布为O型38．91％，B型27．30％，A型26．51％，AB型7．28％，二者间差异无显著性。结论ABO血型分布特点与MODS发病易感性无明显相关性，对MODS发病不具有预测价值。